Borderline lepromatous leprosy (Q95184): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed an Item |
||||||||||||||
| (6 intermediate revisions by the same user not shown) | |||||||||||||||
| description / pt-br | description / pt-br | ||||||||||||||
A hanseníase borderline-lepromatosa (BL) é semelhante à hanseníase lepromatosa (virchowiana), mas a presença de alguma resposta imune mediada por células à infecção impede a proliferação irrestrita de bacilos na pele. É caracterizada por grande número de máculas, pápulas e placas mal definidas, com tendência a se distribuir simetricamente. A neuropatia tende a ser do tipo "botas e luvas" difusa. O início do tratamento, no entanto, pode ser acompanhado pela recuperação da imunidade mediada por células e um risco de lesão nervosa grave (reação de aumento/reação Tipo I) [TAG Dermatologia]. | |||||||||||||||
| description / en | description / en | ||||||||||||||
Borderline lepromatous (BL) leprosy is similar to lepromatous leprosy but the presence of some cell-mediated immune response to infection prevents the unfettered proliferation of bacilli in the skin. It is characterised by large numbers of poorly-defined macules, papules and plaques with a tendency to be distributed symmetrically. Neuropathy tends to be of a diffuse "glove and stocking" type. Initiation of treatment, however, may be accompanied by recovery of cell-mediated immunity and a risk of severe nerve damage (upgrading reaction/Type I reaction) [Dermatology TAG]. | |||||||||||||||
| Property / Canonical URI | |||||||||||||||
| Property / Canonical URI: https://id.who.int/icd/entity/1888276943 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / CURIE | |||||||||||||||
CID11:ID_1888276943 | |||||||||||||||
| Property / CURIE: CID11:ID_1888276943 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Canary Token | |||||||||||||||
dki-india-ID_1888276943 | |||||||||||||||
| Property / Canary Token: dki-india-ID_1888276943 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Verification Status | |||||||||||||||
Concluído | |||||||||||||||
| Property / Verification Status: Concluído / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
15 August 2026
| |||||||||||||||
| Property / Collection date: 15 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 10:54, 16 August 2026
Borderline lepromatous (BL) leprosy is similar to lepromatous leprosy but the presence of some cell-mediated immune response to infection prevents the unfettered proliferation of bacilli in the skin. It is characterised by large numbers of poorly-defined macules, papules and plaques with a tendency to be distributed symmetrically. Neuropathy tends to be of a diffuse "glove and stocking" type. Initiation of treatment, however, may be accompanied by recovery of cell-mediated immunity and a risk of severe nerve damage (upgrading reaction/Type I reaction) [Dermatology TAG].
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | ID_1888276943 |
||
| English | Borderline lepromatous leprosy |
Borderline lepromatous (BL) leprosy is similar to lepromatous leprosy but the presence of some cell-mediated immune response to infection prevents the unfettered proliferation of bacilli in the skin. It is characterised by large numbers of poorly-defined macules, papules and plaques with a tendency to be distributed symmetrically. Neuropathy tends to be of a diffuse "glove and stocking" type. Initiation of treatment, however, may be accompanied by recovery of cell-mediated immunity and a risk of severe nerve damage (upgrading reaction/Type I reaction) [Dermatology TAG]. |
Statements
CID11:ID_1888276943
0 references
dki-india-ID_1888276943
0 references
Concluído
0 references
15 August 2026
0 references
